ADMA Biologics Stock Performance Shares of NASDAQ ADMA opened at $18.67 on Tuesday. The company has a market capitalization of $4.41 billion, a PE ratio of 66.68 and a beta of 0.60. The company ...

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that ...

PARIS, March 17, 2025--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing ...

Feb. 19, 2025 /PRNewswire/ -- Lam Research Corp. (Nasdaq: LRCX) today unveiled ALTUS ® Halo, the world's first atomic layer deposition (ALD) tool that harnesses the capabilities of the metal ...

RAMSEY, N.J. (AP) — RAMSEY, N.J. (AP) — Adma Biologics Inc. (ADMA) on Monday reported fourth-quarter net income of $111.9 million, after reporting a loss in the same period a year earlier.

SHANGHAI, Feb. 21, 2025 /PRNewswire/ -- Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced its continued collaboration with Mabgeek in advancing MG ...

In a report released today, Scott Fletcher from CIBC maintained a Hold rating on Altus Group Limited (AIF – Research Report), with a price target of C$57.00. The company’s shares opened today ...

Welcome to Lab Dish, a new First Opinion column on regenerative medicine from Paul Knoepfler. With all the uncertainties surrounding the Food and Drug Administration under Trump 2.0, the recent ...

--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application ...

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the company won two awards from the annual CDMO Leadership awards ...